NCT02476019

A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients

A Double Blind, Randomized, Placebo-controlled, Single Center, Phase 2a Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 463588 (ISIS-FGFR4RX, an Antisense Inhibitor of Fibroblast Growth Factor Receptor 4) Administered Subcutaneously Once Weekly for 13 Weeks in Obese Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Ionis Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-FGFR4RX.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	ISIS-FGFR4RX	ISIS-FGFR4RX administered subcutaneously
DRUG	Placebo	Placebo administered subcutaneously

Timeline

• Start date: 2015-06-01
• Primary completion: 2016-07-01
• Completion: 2016-09-01
• First posted: 2015-06-19
• Last updated: 2018-06-25

Locations

1 site across 1 country: United States